Beam Therapeutics (BEAM) vs Relay Therapeutics (RLAY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Relay Therapeutics (RLAY) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 207.9% versus a loss of 1.4%. Over five years, RLAY leads with a -47.4% price change compared with -73.4% for BEAM. Relay Therapeutics is the larger company by market cap ($3.93 billion vs $2.56 billion), about 1.5 times the size, while Beam Therapeutics is growing revenue faster (+120.0% vs +53.4%).
Beam Therapeutics converts more of its revenue into profit, with a net margin of -57.2% versus -1800.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | RLAY |
|---|---|---|
| Share price | $24.77 | $17.95 |
| Market cap | $2.56B | $3.93B |
| 1-day change | -1.82% | -4.22% |
| YTD return | -10.64% | +112.17% |
| 1-year return | -1.43% | +207.89% |
| 5-year return | -73.41% | -47.38% |
| EPS (TTM) | $-0.68 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $139.74M | $15.36M |
| Revenue growth (YoY) | +120.01% | +53.44% |
| Net income (latest FY) | $-79.99M | $-276.48M |
| Operating margin | -274.57% | -1971.59% |
| Net margin | -57.24% | -1800.58% |
| 52-week high | $38.26 | $21.27 |
| 52-week low | $20.23 | $5.85 |
| Distance from 52-week high | -35.26% | -15.61% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +110.54% | +53.65% |
| Average volume | 1.92M | 2.80M |
| Shares outstanding | 103.29M | 219.14M |
| Employees | 540 | 202 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLAY has outperformed BEAM by 209.3 percentage points over the past year.
- Beam Therapeutics is more profitable, keeping -57.2 cents of every revenue dollar as net income versus -1800.6 cents for Relay Therapeutics.
- Beam Therapeutics grew revenue faster in its latest fiscal year (+120.01% vs +53.44%).
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
About Relay Therapeutics
RLAY stock →Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 202 employees
BEAM vs RLAY FAQ
Which is bigger, Beam Therapeutics or Relay Therapeutics?
Relay Therapeutics (RLAY) is larger, with a market capitalization of $3.93B compared with $2.56B for Beam Therapeutics (BEAM).
Which stock has performed better over the past year, BEAM or RLAY?
RLAY returned +207.89% over the past 12 months, compared with -1.43% for BEAM (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Relay Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.